Terns [TERN] vs Bio-Techne [TECH] Detailed Stock Comparison

Terns Pharmaceuticals Inc.

NASDAQ
Loading...

Bio-Techne Corporation

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Terns Pharmaceuticals Inc. wins in 3 metrics, Bio-Techne Corporation wins in 11 metrics, with 0 ties. Bio-Techne Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Terns Pharmaceuticals Inc. Bio-Techne Corporation Better
P/E Ratio (TTM) N/A 117.16 N/A
Price-to-Book Ratio 5.90 4.55 Bio-Techne Corporation
Debt-to-Equity Ratio 0.09 20.07 Terns Pharmaceuticals Inc.
PEG Ratio -35.92 -0.82 Bio-Techne Corporation
EV/EBITDA -46.07 28.87 Bio-Techne Corporation
Profit Margin (TTM) 0.00% 6.41% Bio-Techne Corporation
Operating Margin (TTM) 0.00% 14.51% Bio-Techne Corporation
EBITDA Margin (TTM) N/A 14.51% N/A
Return on Equity -14.23% 3.80% Bio-Techne Corporation
Return on Assets (TTM) -9.91% 6.09% Bio-Techne Corporation
Free Cash Flow (TTM) $-82.18M $256.55M Bio-Techne Corporation
Dividend Yield N/A 0.62% N/A
1-Year Return 1,738.54% 6.89% Terns Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) N/A 7.35 N/A
Enterprise Value $5.07B $9.19B Bio-Techne Corporation
EV/Revenue Ratio N/A 7.56 N/A
Gross Profit Margin (TTM) N/A 62.72% N/A
Revenue per Share (TTM) N/A $8 N/A
Earnings per Share (Diluted) $-1.03 $0.49 Bio-Techne Corporation
Beta (Stock Volatility) -0.38 1.47 Terns Pharmaceuticals Inc.
Short % of Float 11.71% 5.09% Bio-Techne Corporation

Terns Pharmaceuticals Inc. vs Bio-Techne Corporation Stock Performance Analysis

Loading Price Chart...

TERN
TECH

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Terns Pharmaceuticals Inc.0.00%0.00%0.46%33.78%107.16%32.01%
Bio-Techne Corporation4.02%6.69%29.72%15.08%-4.29%-5.83%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Terns Pharmaceuticals Inc.1,738.54%424.78%232.60%187.93%187.93%187.93%
Bio-Techne Corporation6.89%-31.20%-49.99%96.15%179.21%318.28%

Performance & Financial Health Analysis: Terns Pharmaceuticals Inc. vs Bio-Techne Corporation

MetricTERNTECH
Market Information
Market Cap i$6.10B$9.07B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i6,615,4622,151,790
90 Day Avg. Volume i9,441,8672,370,067
Last Close$52.95$56.17
52 Week Range$2.65 - $53.19$43.20 - $72.16
% from 52W High-0.45%-22.16%
All-Time High$53.19 (Mar 26, 2026)$135.96 (Sep 20, 2021)
% from All-Time High-0.45%-58.69%
Growth Metrics
Quarterly Revenue GrowthN/A-0.01%
Quarterly Earnings GrowthN/A0.14%
Financial Health
Profit Margin (TTM) i0.00%0.06%
Operating Margin (TTM) i0.00%0.15%
Return on Equity (TTM) i-0.14%0.04%
Debt to Equity (MRQ) i0.0920.07
Cash & Liquidity
Book Value per Share (MRQ)$8.96$12.62
Cash per Share (MRQ)$8.83$0.93
Operating Cash Flow (TTM) i$-82,176,000$251.25M
Levered Free Cash Flow (TTM) i$-55,480,500$274.30M
Dividends
Last 12-Month Dividend Yield iN/A0.62%
Last 12-Month Dividend iN/A$0.40

Valuation & Enterprise Metrics Analysis: Terns Pharmaceuticals Inc. vs Bio-Techne Corporation

MetricTERN (Apr 22, 2026)TECH (Nov 10, 2025)
Price Ratios
P/E Ratio (TTM) iN/A117.16
Forward P/E i-35.9226.21
PEG Ratio i-35.92-0.82
Price to Sales (TTM) iN/A7.35
Price to Book (MRQ) i5.904.55
Market Capitalization
Market Capitalization i$6.10B$9.07B
Enterprise Value i$5.07B$9.19B
Enterprise Value Metrics
Enterprise to Revenue iN/A7.56
Enterprise to EBITDA i-46.0728.87
Risk & Other Metrics
Beta i-0.381.47
Book Value per Share (MRQ) i$8.96$12.62

Financial Statements Comparison: Terns Pharmaceuticals Inc. vs Bio-Techne Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricTERN (2025)TECH (2025)
Revenue/Sales i01.22B
Cost of Goods Sold iN/A429.36M
COGS % of Revenue i-35.2%
Gross Profit iN/A790.27M
Gross Margin i-64.8%
Research & Development i77.89M99.50M
Operating Income (EBIT) i-110.12M242.80M
Operating Margin i-19.9%
EBITDA i-109.62M357.57M
EBITDA Margin i-29.3%
Pre-Tax Income i-95.63M98.46M
Pre-Tax Income % of Revenue i-8.1%
Income Tax i581,00025.06M
Income Tax % of Revenue i-2.1%
Net Income (Profit) i-96.21M73.40M
Profit Margin i-6.0%

Balance Sheet & Liquidity Metrics

MetricTERN (2025)TECH (2025)
Cash & Equivalents i524.75M162.19M
Total Current Assets i1.02B608.30M
Total Current Assets % of Revenue i-49.9%
Total Current Liabilities i16.41M175.85M
Total Current Liabilities % of Revenue i-14.4%
Long-Term Debt i445,000429.96M
Long-Term Debt % of Revenue i-35.3%
Total Shareholders Equity i1.01B1.92B
Retained Earnings i-517.69M1.07B
Retained Earnings % of Revenue i-87.4%
Property, Plant & Equipment i073.40M

Cash Flow Statement Comparison

MetricTERN (2025)TECH (2025)
Operating Cash Flow i-82.74M185.64M
Operating Cash Flow % of Revenue i-15.2%
Capital Expenditures i0-31.01M
Free Cash Flow i-82.18M256.55M
FCF Margin i-21.0%
Debt Repayment iN/A-77.00M
Common Stock Repurchase iN/A-275.73M

Short Interest & Institutional Ownership Analysis

MetricTERNTECH
Shares Short i13.51M6.94M
Short Ratio i1.722.59
Short % of Float i11.71%5.09%
Shares Outstanding i112.32M154.97M
Float Shares i115.12M153.94M
% Held by Insiders i0.53%0.28%
% Held by Institutions i109.57%102.89%
% Held by Public i-10.10%-3.17%

Dividend Analysis & Yield Comparison: Terns Pharmaceuticals Inc. vs Bio-Techne Corporation

MetricTERNTECH
Last 12-Month Dividend iN/A$0.40
Last 12-Month Dividend Yield iN/A0.62%
3-Year Avg Annual Dividend iN/A$0.32
3-Year Avg Dividend Yield iN/A0.12%
3-Year Total Dividends iN/A$0.96
Ex-Dividend DateN/AFeb 13, 2026